Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions mention specific findings from the publication, such as the equal survival rates between genders and the increased complication rates observed in women. Phrases like 'fantastic paper' and 'very interesting findings' reflect a tone of enthusiasm and respect for the research, while discussions about ongoing disparities and the need for patient counseling highlight the urgency and relevance of the findings in the medical community.
The majority of discussions reflect a strong endorsement of the publication's findings, highlighting agreement on the significance of examining clinical outcomes in both women and men.
Participants exhibit a high level of curiosity regarding the differing impacts of left ventricular assist devices (LVADs) on women compared to men.
While there are surface-level acknowledgments of the research, deeper discussions surrounding methods and implications were present, albeit not extensively.
Many contributors believe the research carries substantial implications for future clinical practices and understanding disparities in treatment outcomes.
Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read the phenomenal paper by @DhariniRamu et al on “Clinical Outcomes With HM3 #LVAD Among Women and Men”
JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy. "We have to counsel patients that this therapy will offer longevity, and there are certain risks." @JACCJournals #JACCHF https://t.co/qY3Z6JdQIH Full interview https://t.co/4CsZdjaeFG
New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates of: GI blees, stroke, RV failure, and major infections https://t.co/o0fq6F2Tll #HeartFailure #HM3 #HeartMate3 https://t.co/YuWeF66M1N
Congratulations to @DhariniRamu and @rcogswell_umn on having their publication in JACC Heart Failure! Checkout the full article here: https://t.co/PccxlwVlS7 https://t.co/SVPL1OcWgG
New in #JACCHF: Compared with men, women receiving HM3 had the following 2-year outcomes:
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Although infrequent in occurrence, smaller LVEDD (<55 mm) is associated with increased risk for early and late mortality https://t.co/OOekLubXPS https://t.co/FasJgNtbPb
JACC Heart Failure editor Dr. Eiran Gorodeski and senior author Dr. Melana Yuzefpolskaya discuss the findings of a study on clinical outcomes with fully magnetically levitated left ventricular assist devices (LVADs)…
Dr. Melana Yuzefpolskaya from NewYork Presbyterian Columbia discusses the characteristics, adverse events, and outcomes of LVAD therapy among women and men. The study reveals that women, though a minority, experience…
RT @drbennisahmed: Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Al…
RT @drbennisahmed: Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Al…
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Although infrequent in occurrence, smaller LVEDD (<55 mm) is associated with increased risk for early and late mortality https://t.co/OOekLubXPS https://t.co/FasJgNtbPb
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
New in #JACCHF: Compared with men, women receiving HM3 had the following 2-year outcomes:
RT @JACCJournals: New in #JACCHF: Compared with men, women receiving HM3 had the following 2-year outcomes:
New in #JACCHF: Compared with men, women receiving HM3 had the following 2-year outcomes:
RT @adrianjdasilva: New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates…
RT @adrianjdasilva: New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates…
RT @adrianjdasilva: New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates…
RT @adrianjdasilva: New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates…
RT @adrianjdasilva: New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates…
RT @adrianjdasilva: New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates…
RT @adrianjdasilva: New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates…
New in JACC HF: Compared with men, women receiving HM3 had the following 2-year outcomes: · Equal survival · ↑ Rates of: GI blees, stroke, RV failure, and major infections https://t.co/o0fq6F2Tll #HeartFailure #HM3 #HeartMate3 https://t.co/YuWeF66M1N
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
RT @EiranGorodeski: JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy.…
JACC: HF video podcast. I interviewed Dr. Melana Yuzefpolskaya about differences among women and men with LVAD therapy. "We have to counsel patients that this therapy will offer longevity, and there are certain risks." @JACCJournals #JACCHF https://t.co/qY3Z6JdQIH Full interview https://t.co/4CsZdjaeFG
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
@DrMarthaGulati @Jcontreras75 @JACCJournals Thanks Martha. @DrMarthaGulati Fantastic paper by @DhariniRamu & team with very interesting findings. @JACCJournals #JACCHF https://t.co/L7W0WbJCAi
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
RT @docbhardwaj: Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read t…
Pleased to share our editorial in @JACCJournals #JACCHF on “Disparities in women needing #MCS” with @Jcontreras75 Read the phenomenal paper by @DhariniRamu et al on “Clinical Outcomes With HM3 #LVAD Among Women and Men”
RT @UMN_DCVM: Congratulations to @DhariniRamu and @rcogswell_umn on having their publication in JACC Heart Failure! Checkout the full art…
RT @UMN_DCVM: Congratulations to @DhariniRamu and @rcogswell_umn on having their publication in JACC Heart Failure! Checkout the full art…
Congratulations to @DhariniRamu and @rcogswell_umn on having their publication in JACC Heart Failure! Checkout the full article here: https://t.co/PccxlwVlS7 https://t.co/SVPL1OcWgG